Evidence map›Paper›PMID 41181577›Full record

ArticleFujita medical journal2025

Impact of

Ryoko Ichikawa, Tamotsu Sudo, Kyohei Takada, Akiko Ohwaki, Mayuko Ito, Yusuke Shimizu, Mayu Takeda, Eiji Sugihara, Tetsuya Takimoto, Haruki Nishizawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fujita medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ryoko IchikawaDepartment of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Tamotsu SudoDepartment of Cancer Genetics & Genomics, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Kyohei TakadaDepartment of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Akiko OhwakiDepartment of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Mayuko ItoDepartment of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Yusuke ShimizuDepartment of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Mayu TakedaFaculty of Health and Medical Sciences, Aichi Syukutoku University, Nagakute, Aichi, Japan.
Eiji SugiharaDivision of Gene Regulation, Oncology Innovation Center, Fujita Health University, Toyoake, Aichi, Japan.
Tetsuya TakimotoDivision of Date Science, Oncology Innovation Center, Fujita Health University, Toyoake, Aichi, Japan.
Haruki NishizawaDepartment of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Uterine carcinosarcoma (UCS) is a rare and aggressive gynecological cancer with high recurrence rates and is associated with a poor prognosis. It is also characterized by a high frequency of copy number alterations (CNAs). This study aimed to determine which gene CNA contributes to progression-free survival (PFS) in patients with UCS to identify potential prognostic biomarkers and therapeutic targets. Methods: DNA was extracted from formalin-fixed paraffin-embedded tissues of surgical specimens from 24 patients with UCS who were treated at Fujita Health University. Using the PleSSision-Rapid test, the mutation information of 145 cancer genes was analyzed. Oncoplot analysis was used to visualize gene mutation profiles. χ Results: The most frequently observed gene mutation was Conclusion: In patients with UCS,

Indexed as

mTOR inhibitorTSC2 lossUterine carcinosarcoma

Identifiers

PMID41181577
PMCPMC12576405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.